Patents by Inventor Friederike Hesse
Friederike Hesse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210347916Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.Type: ApplicationFiled: June 25, 2021Publication date: November 11, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
-
Publication number: 20210324108Abstract: The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: October 31, 2018Publication date: October 21, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Maria AMANN, Claudia FERRARA KOLLER, Reto FLURY, Guy GEORGES, Sandra GRAU-RICHARDS, Alexander HAAS, Friederike HESSE, Sabine IMHOF-JUNG, Christian KLEIN
-
Publication number: 20200347115Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising two different fusion polypeptides that comprise a spacer domain, an antigen binding domain and three ectodomains of a TNF ligand member or fragments thereof, wherein two of said ectodomains are separated from each other by a spacer domain comprising at least 25 amino acids and wherein the two fusion polypeptides are covalently associated to each other in the spacer domainType: ApplicationFiled: April 29, 2020Publication date: November 5, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Harald Duerr, Claudia Ferrara Koller, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Christina Claus, Wei Xu
-
Publication number: 20190389971Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.Type: ApplicationFiled: November 1, 2018Publication date: December 26, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
-
Publication number: 20170267736Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with man amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: ApplicationFiled: January 20, 2017Publication date: September 21, 2017Inventors: Friederike HESSE, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
-
Patent number: 9724425Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: GrantFiled: September 10, 2014Date of Patent: August 8, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
-
Patent number: 9587006Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: GrantFiled: February 4, 2011Date of Patent: March 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Friederike Hesse, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
-
Patent number: 9487576Abstract: Herein is reported a method for the recombinant production of a polypeptide, which comprises the dipeptide AR, characterized in that the method comprises the recovering of the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the dipeptide AR comprised in the polypeptide is encoded by the oligonucleotide gca cgt, or the oligonucleotide gcg cgt, or the oligonucleotide gcc cgt.Type: GrantFiled: August 29, 2014Date of Patent: November 8, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Patent number: 9481706Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second cType: GrantFiled: April 7, 2014Date of Patent: November 1, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Gabel, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
-
Publication number: 20150099699Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: September 10, 2014Publication date: April 9, 2015Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
-
Publication number: 20150064746Abstract: Herein is reported a method for the recombinant production of a polypeptide, which comprises the tripeptide QKK, characterized in that the method comprises the step of recovering the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the tripeptide QKK comprised in the polypeptide is encoded by the oligonucleotide cag aaa aaa or the oligonucleotide caa aag aaa.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Publication number: 20150056656Abstract: Herein is reported a method for the recombinant production of a polypeptide, which comprises the dipeptide AR, characterized in that the method comprises the recovering of the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the dipeptide AR comprised in the polypeptide is encoded by the oligonucleotide gca cgt, or the oligonucleotide gcg cgt, or the oligonucleotide gcc cgt.Type: ApplicationFiled: August 29, 2014Publication date: February 26, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Publication number: 20150044718Abstract: Herein is reported a method for obtaining a polypeptide by an immobilized metal ion affinity chromatography from a pro-polypeptide that comprise at its N- or C-terminus an metal ion affinity chromatography tag and a protease cleavage site comprising the step of recovering the polypeptide from the immobilized metal ion affinity chromatography column by incubating the bound pro-polypeptide with a protease, whereby the immobilized metal ion affinity chromatography material has been washed at least once with an urea solution.Type: ApplicationFiled: February 27, 2013Publication date: February 12, 2015Inventors: Roberto Falkenstein, Adelbert Grossmann, Friederike Hesse
-
Patent number: 8877895Abstract: A pro-polypeptide which is useful for the expression of a polypeptide of interest in a prokaryotic cell. Therefore the pro-polypeptide is fused to the N-terminus of the polypeptide of interest. The pro-polypeptide as reported herein provides for improved expression yields and improves the handling of the fusion polypeptide (downstream processing, purification). For example, efficient endotoxin removal is effected while the protein of interest comprising the pro-polypeptide is bound e.g. to an affinity chromatography material. Thereafter the pro-polypeptide can efficiently be cleaved from the polypeptide of interest by the incorporated protease cleavage site with the cognate protease.Type: GrantFiled: August 25, 2011Date of Patent: November 4, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Publication number: 20140220633Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second cType: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Gabel, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
-
Patent number: 8552158Abstract: Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: GrantFiled: August 29, 2007Date of Patent: October 8, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar
-
Patent number: 8476232Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: GrantFiled: August 21, 2012Date of Patent: July 2, 2013Assignee: Hoffman-La Roche Inc.Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Publication number: 20130065831Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.Type: ApplicationFiled: August 21, 2012Publication date: March 14, 2013Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar, Hans-Joachim Schoenfeld
-
Publication number: 20120322732Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: July 18, 2012Publication date: December 20, 2012Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
-
Publication number: 20120309679Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: ApplicationFiled: February 4, 2011Publication date: December 6, 2012Inventors: Friederike Hesse, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross